Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 194

Sort by

Sort Order Select

Journal Articles

A phase I/II trial of azacitidine and venetoclax in previously untreated Myelodysplastic Syndromes

Blood (2025) 146 (Supplement 1): 5647.

https://doi.org/10.1182/blood-2025-5647

Published: 2025

Journal Articles

Complex cytogenetics in myeloid malignancies: A deconstruction analysis redefining complex karyotypes

Alex Bataller, Alexandre Bazinet, Guillermo Montalban-Bravo, Kelly Chien, Danielle Hammond, Ian Bouligny, Jayastu Senapati, Koji Sasaki, Ghayas Issa, Nicholas Short, Tapan Kadia, Rashmi Kanagal-Shamanna, Sanam Loghavi, Guilin Tang, Elias Jabbour, Farhad Ravandi, Hagop Kantarjian, Guillermo Garcia-Manero

Blood (2025) 146 (Supplement 1): 5641.

https://doi.org/10.1182/blood-2025-5641

Published: 2025

Journal Articles

RUNX1 mutations define a high-risk biological subset of chronic myelomonocytic leukemia and cooperate with ASXL1 mutations to drive leukemic transformation

Blood (2025) 146 (Supplement 1): 3857.

https://doi.org/10.1182/blood-2025-3857

Published: 2025

Journal Articles

Consideration of genomic determinants improves the diagnostic accuracy of oligomonocytic chronic myelomonocytic leukemia

Blood (2025) 146 (Supplement 1): 3849.

https://doi.org/10.1182/blood-2025-3849

Published: 2025

Journal Articles

Multimodal assessment of chronic myelomonocytic leukemia with extramedullary involvement reveals RAS pathway activation, adverse outcomes and epithelial-mesenchymal transition

Blood (2025) 146 (Supplement 1): 3848.

https://doi.org/10.1182/blood-2025-3848

Published: 2025

Journal Articles

Oral decitabine/cedazuridine in combination with venetoclax in treatment-naïve high-risk myelodysplastic syndrome or chronic myelomonocytic leukemia: Updates of a Phase 1/2 clinical trial

Blood (2025) 146 (Supplement 1): 237.

https://doi.org/10.1182/blood-2025-237

Published: 2025

Journal Articles

Impact of pre-allogeneic stem cell transplantation (SCT) disease characteristics, therapy, and response on post-SCT outcomes in higher risk myelodysplastic syndromes

Blood (2025) 146 (Supplement 1): 6075.

https://doi.org/10.1182/blood-2025-6075

Published: 2025

Journal Articles

Characteristics and outcomes of CEBPA bZIP in-frame mutations in de novo and treated secondary acute myeloid leukemia

Blood (2025) 146 (Supplement 1): 5167.

https://doi.org/10.1182/blood-2025-5167

Published: 2025

Journal Articles

Toward precision pathology: Deep learning supported fibrosis grading augments performance of international hematopathologists in a large real-world cohort

Blood (2025) 146 (Supplement 1): 4335.

https://doi.org/10.1182/blood-2025-4335

Published: 2025

Journal Articles

Allogeneic stem cell transplantation-related outcomes in chronic myelomonocytic leukemia: Data from a large academic center

Blood (2025) 146 (Supplement 1): 4294.

https://doi.org/10.1182/blood-2025-4294

Published: 2025

Journal Articles

Dichotomy of TP53 mutant AML MRD microenvironment: Spatially segregated immunosuppressive mechanisms and niche-specific structural support

Hideaki Mizuno, Yuki Nishida, Edward Ayoub, Andrea Bedoy, Akshay Basi, Danielle L Stolley, Xuehong Gui, Jared Burks, Rashmi Kanagal-Shamanna, Michael Andreeff

Blood (2025) 146 (Supplement 1): 6714.

https://doi.org/10.1182/blood-2025-6714

Published: 2025

Journal Articles

Outcomes of hypomethylating agent failure in patients with myelodysplastic syndromes

Blood (2025) 146 (Supplement 1): 2075.

https://doi.org/10.1182/blood-2025-2075

Published: 2025

Journal Articles

Dynamic biomarker trajectories predict outcomes in AML-associated hemophagocytic lymphohistiocytosis

Blood (2025) 146 (Supplement 1): 604.

https://doi.org/10.1182/blood-2025-604

Published: 2025

Journal Articles

Prognostic and therapeutic impact of FLT3 mutations and allelic burden in myelodysplastic syndromes and chronic myelomonocytic leukemia: Results from a multicenter cohort study

Blood (2025) 146 (Supplement 1): 2085.

https://doi.org/10.1182/blood-2025-2085

Published: 2025

Journal Articles

Clinical and biological correlates of blast-transformed chronic myelomonocytic leukemia (CMML): A multicenter study of 493 paired cases at chronic phase and at blast transformation

Blood (2025) 146 (Supplement 1): 2081.

https://doi.org/10.1182/blood-2025-2081

Published: 2025

Journal Articles

Causes of Death in Patients with Myelodysplastic Syndrome and Spliceosome Mutations

Arjun S. Peddireddy, Panayiotis Kontoyiannis, Koji Sasaki, Kelly S. Chien, Jayastu Senapati, Guillermo Montalban-Bravo, Courtney D. DiNardo, Gautam Borthakur, Rashmi Kanagal-Shamanna, Carlos E. Bueso-Ramos, Sherry Pierce, Hagop M. Kantarjian, Guillermo Garcia-Manero, Samuel Urrutia

Blood (2024) 144 (Supplement 1): 6704.

https://doi.org/10.1182/blood-2024-202540

Published: 2024

Journal Articles

Survival Benefits of Complete Cytogenetic Response in Patients with Newly Diagnosed Myelodysplastic Syndrome

Roberta Santos Azevedo, Hagop M. Kantarjian, Elias Jabbour, Rashmi Kanagal-Shamanna, Kelly S. Chien, Danielle Hammond, Samuel Urrutia, Carlos E. Bueso-Ramos, Keyur P. Patel, Guillermo Montalban-Bravo, Nicholas J. Short, Naval Daver, Gautam Borthakur, Tapan M. Kadia, William G. Wierda, Guillermo Garcia-Manero, Koji Sasaki

Blood (2024) 144 (Supplement 1): 6727.

https://doi.org/10.1182/blood-2024-201864

Published: 2024

Journal Articles

Acalabrutinib with Rituximab Is Highly Effective First Line Treatment for Older Patients with Mantle Cell Lymphoma

Blood (2024) 144 (Supplement 1): 3038.

https://doi.org/10.1182/blood-2024-206042

Published: 2024

Journal Articles

A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab with or without Azacitidine in Relapsed or Refractory Myelodysplastic Syndrome

Blood (2024) 144 (Supplement 1): 3212.

https://doi.org/10.1182/blood-2024-205186

Published: 2024

Journal Articles

Spatial Analysis of Human p53 Mutated AML Bone Marrow Reveals Novel MRD Clusters and Spatial Microenvironmental Features of p53 Mutated AML

Hideaki Mizuno, Yuki Nishida, Edward Ayoub, Akshay Basi, Andrea Bedoy, Javier A. Gomez, Jared K. Burks, Rashmi Kanagal-Shamanna, Michael Andreeff

Blood (2024) 144 (Supplement 1): 1301.

https://doi.org/10.1182/blood-2024-209852

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

A phase I/II trial of azacitidine and venetoclax in previously untreated Myelodysplastic Syndromes

Complex cytogenetics in myeloid malignancies: A deconstruction analysis redefining complex karyotypes

RUNX1 mutations define a high-risk biological subset of chronic myelomonocytic leukemia and cooperate with ASXL1 mutations to drive leukemic transformation

Consideration of genomic determinants improves the diagnostic accuracy of oligomonocytic chronic myelomonocytic leukemia

Multimodal assessment of chronic myelomonocytic leukemia with extramedullary involvement reveals RAS pathway activation, adverse outcomes and epithelial-mesenchymal transition

Oral decitabine/cedazuridine in combination with venetoclax in treatment-naïve high-risk myelodysplastic syndrome or chronic myelomonocytic leukemia: Updates of a Phase 1/2 clinical trial

Impact of pre-allogeneic stem cell transplantation (SCT) disease characteristics, therapy, and response on post-SCT outcomes in higher risk myelodysplastic syndromes

Characteristics and outcomes of CEBPA bZIP in-frame mutations in de novo and treated secondary acute myeloid leukemia

Toward precision pathology: Deep learning supported fibrosis grading augments performance of international hematopathologists in a large real-world cohort

Allogeneic stem cell transplantation-related outcomes in chronic myelomonocytic leukemia: Data from a large academic center

Dichotomy of TP53 mutant AML MRD microenvironment: Spatially segregated immunosuppressive mechanisms and niche-specific structural support

Outcomes of hypomethylating agent failure in patients with myelodysplastic syndromes

Dynamic biomarker trajectories predict outcomes in AML-associated hemophagocytic lymphohistiocytosis

Prognostic and therapeutic impact of FLT3 mutations and allelic burden in myelodysplastic syndromes and chronic myelomonocytic leukemia: Results from a multicenter cohort study

Clinical and biological correlates of blast-transformed chronic myelomonocytic leukemia (CMML): A multicenter study of 493 paired cases at chronic phase and at blast transformation

Causes of Death in Patients with Myelodysplastic Syndrome and Spliceosome Mutations

Survival Benefits of Complete Cytogenetic Response in Patients with Newly Diagnosed Myelodysplastic Syndrome

Acalabrutinib with Rituximab Is Highly Effective First Line Treatment for Older Patients with Mantle Cell Lymphoma

A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab with or without Azacitidine in Relapsed or Refractory Myelodysplastic Syndrome

Spatial Analysis of Human p53 Mutated AML Bone Marrow Reveals Novel MRD Clusters and Spatial Microenvironmental Features of p53 Mutated AML

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only